Vasculopathy, Immunodeficiency, and Bone Marrow Failure: The Intriguing Syndrome Caused by Deficiency of Adenosine Deaminase 2
暂无分享,去创建一个
[1] S. Ozen,et al. Deficiency of adenosine deaminase 2; special focus on central nervous system imaging. , 2019, Journal of neuroradiology. Journal de neuroradiologie.
[2] Todd W. Lyons,et al. Disrupted N-linked glycosylation as a disease mechanism in deficiency of ADA2. , 2018, The Journal of allergy and clinical immunology.
[3] K. Heimdal,et al. A decision tree for the genetic diagnosis of deficiency of adenosine deaminase 2 (DADA2): a French reference centres experience , 2018, European Journal of Human Genetics.
[4] S. Mustjoki,et al. ADA2 deficiency: Clonal lymphoproliferation in a subset of patients , 2018, The Journal of allergy and clinical immunology.
[5] S. Holland,et al. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. , 2017, Blood.
[6] M. Hershfield,et al. Deficiency of Adenosine Deaminase 2 (DADA2), an Inherited Cause of Polyarteritis Nodosa and a Mimic of Other Systemic Rheumatologic Disorders , 2017, Current Rheumatology Reports.
[7] W. Schmidt,et al. Autoimmune phenotype with type I interferon signature in two brothers with ADA2 deficiency carrying a novel CECR1 mutation , 2017, Pediatric Rheumatology.
[8] V. Lougaris,et al. Screening of 181 Patients With Antibody Deficiency for Deficiency of Adenosine Deaminase 2 Sheds New Light on the Disease in Adulthood , 2017, Arthritis & rheumatology.
[9] J. Kros,et al. CECR1-mediated cross talk between macrophages and vascular mural cells promotes neovascularization in malignant glioma , 2017, Oncogene.
[10] G. Damonte,et al. ADA2 deficiency (DADA2) as an unrecognised cause of early onset polyarteritis nodosa and stroke: a multicentre national study , 2017, Annals of the rheumatic diseases.
[11] A. Zavialov,et al. Human adenosine deaminases ADA1 and ADA2 bind to different subsets of immune cells , 2017, Cellular and Molecular Life Sciences.
[12] C. Kuhl,et al. Stroke as Initial Manifestation of Adenosine Deaminase 2 Deficiency , 2016, Neuropediatrics.
[13] Masayuki Sakurai,et al. Functions of the RNA Editing Enzyme ADAR1 and Their Relevance to Human Diseases , 2016, Genes.
[14] M. Hershfield,et al. Extending the Clinical Phenotype of Adenosine Deaminase 2 Deficiency. , 2016, The Journal of pediatrics.
[15] F. Penco,et al. Monogenic polyarteritis: the lesson of ADA2 deficiency , 2016, Pediatric Rheumatology.
[16] S. Holland,et al. Adenosine deaminase type 2 deficiency masquerading as GATA2 deficiency: Successful hematopoietic stem cell transplantation. , 2016, The Journal of allergy and clinical immunology.
[17] Y. Crow,et al. ADA2 deficiency: case report of a new phenotype and novel mutation in two sisters , 2016, RMD Open.
[18] J. Beckmann,et al. IL-17 receptor A and adenosine deaminase 2 deficiency in siblings with recurrent infections and chronic inflammation. , 2016, The Journal of allergy and clinical immunology.
[19] N. Klein,et al. Deficiency of Adenosine Deaminase Type 2: A Description of Phenotype and Genotype in Fifteen Cases , 2016, Arthritis & rheumatology.
[20] H. Cao,et al. Deficiency of Adenosine Deaminase 2 Causes Antibody Deficiency , 2016, Journal of Clinical Immunology.
[21] Qing Zhou,et al. Adenosine deaminase 2 deficiency presenting as spastic paraplegia and systemic vasculitis , 2016, Journal of Neurology.
[22] R. Krance,et al. Adenosine Deaminase 2 Deficiency As a Cause of Pure Red Cell Aplasia Mimicking Diamond Blackfan Anemia , 2015 .
[23] A. Zavialov,et al. Dermatologic Features of ADA2 Deficiency in Cutaneous Polyarteritis Nodosa. , 2015, JAMA dermatology.
[24] P. Nederkoorn,et al. Phenotypic variability in patients with ADA2 deficiency due to identical homozygous R169Q mutations , 2015, Pediatric Rheumatology.
[25] P. Seeburg,et al. RNA editing by ADAR1 prevents MDA5 sensing of endogenous dsRNA as nonself , 2015, Science.
[26] S. Özen,et al. A case series of adenosine deaminase 2 deficient patients emphasizing treatment and genotype-phenotype correlations , 2015, The Journal of Rheumatology.
[27] C. Wouters,et al. Hematopoietic stem cell transplantation rescues the immunologic phenotype and prevents vasculopathy in patients with adenosine deaminase 2 deficiency , 2015, The Journal of allergy and clinical immunology.
[28] A. Liston,et al. Mutant ADA2 in vasculopathies. , 2014, The New England journal of medicine.
[29] T. Walsh,et al. Mutant adenosine deaminase 2 in a polyarteritis nodosa vasculopathy. , 2014, The New England journal of medicine.
[30] J. Mullikin,et al. Early-onset stroke and vasculopathy associated with mutations in ADA2. , 2014, The New England journal of medicine.
[31] D. Zurakowski,et al. Hypergammaglobulinemia in the pediatric population as a marker for underlying autoimmune disease: a retrospective cohort study , 2013, Pediatric Rheumatology.
[32] John H Livingston,et al. Mutations in ADAR1 cause Aicardi-Goutières syndrome associated with a type I interferon signature , 2012, Nature Genetics.
[33] N. Glaichenhaus,et al. Human adenosine deaminase 2 induces differentiation of monocytes into macrophages and stimulates proliferation of T helper cells and macrophages , 2010, Journal of leukocyte biology.
[34] P. Merkel,et al. Genetics of vasculitis , 2010, Current opinion in rheumatology.
[35] A. Zavialov,et al. Structural Basis for the Growth Factor Activity of Human Adenosine Deaminase ADA2*♦ , 2010, The Journal of Biological Chemistry.
[36] P. Lamprecht,et al. Antineutrophil cytoplasmic antibody-associated vasculitis: autoinflammation, autodestruction and autoimmunity--key to new therapies. , 2008, Trends in immunology.
[37] Pál Pacher,et al. Adenosine receptors: therapeutic aspects for inflammatory and immune diseases , 2006, Nature Reviews Drug Discovery.
[38] Takaya Yamamoto,et al. Human plasma adenosine deaminase 2 is secreted by activated monocytes , 2006, Biological chemistry.
[39] P Woo,et al. EULAR/PReS endorsed consensus criteria* for the classification of childhood vasculitides , 2005, Annals of the rheumatic diseases.
[40] A. Zavialov,et al. Human ADA2 belongs to a new family of growth factors with adenosine deaminase activity. , 2005, The Biochemical journal.
[41] T. Southwood,et al. Incidence of Henoch-Schonlein purpura, Kawasaki disease, and rare vasculitides in children of different ethnic origins , 2002, The Lancet.
[42] P. Bryant,et al. Adenosine deaminase-related growth factors stimulate cell proliferation in Drosophila by depleting extracellular adenosine , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[43] B. Birren,et al. Analysis of the cat eye syndrome critical region in humans and the region of conserved synteny in mice: a search for candidate genes at or near the human chromosome 22 pericentromere. , 2001, Genome research.
[44] B. Roe,et al. The human homolog of insect-derived growth factor, CECR1, is a candidate gene for features of cat eye syndrome. , 2000, Genomics.
[45] H. Shiraishi,et al. Automated enzymatic measurement of adenosine deaminase isoenzyme activities in serum. , 1990, Analytical biochemistry.
[46] D. Pirino,et al. Serum adenosine deaminase activity in HIV positive subjects. A hypothesis on the significance of ADA2. , 1989, Panminerva medica.
[47] F. Martiniuk,et al. Differential expression of adenosine deaminase isozymes in acute leukemia. , 1988, Blood.
[48] E. Giblett,et al. Adenosine-deaminase deficiency in two patients with severely impaired cellular immunity. , 1972, Lancet.
[49] E. Ben-Chetrit,et al. Vasculitis in the autoinflammatory diseases , 2017, Current opinion in rheumatology.
[50] H. Ozdogan,et al. Clinical, imaging and genotypical features of three deceased and five surviving cases with ADA2 deficiency , 2017, Rheumatology International.
[51] A. Wakhlu,et al. Vasculitis and vasculitis-like manifestations in monogenic autoinflammatory syndromes , 2017, Rheumatology International.
[52] R. Petty,et al. Chapter 32 – Vasculitis and Its Classification , 2016 .
[53] P. Merkel,et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. , 2013, Arthritis and rheumatism.
[54] R. Sarı,et al. Correlation of serum levels of adenosine deaminase activity and its isoenzymes with disease activity in rheumatoid arthritis. , 2003, Clinical and experimental rheumatology.
[55] B. Pollara,et al. Characterization of the residual adenosine deaminating activity in the spleen of a patient with combined immunodeficiency disease and adenosine deaminase deficiency. , 1978, Proceedings of the National Academy of Sciences of the United States of America.